Blake Aftab - Net Worth and Insider Trading

Blake Aftab Net Worth

The estimated net worth of Blake Aftab is at least $47,391 dollars as of 2024-04-27. Blake Aftab is the Chief Scientific Officer of Adicet Bio Inc and owns about 28,209 shares of Adicet Bio Inc (ACET) stock worth over $47,391. Details can be seen in Blake Aftab's Latest Holdings Summary section.

Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the assumption that Blake Aftab has not made any transactions after 2022-11-10 and currently still holds the listed stock(s).

Transaction Summary of Blake Aftab

To

Blake Aftab Insider Ownership Reports

Based on ownership reports from SEC filings, as the reporting owner, Blake Aftab owns 1 companies in total, including Adicet Bio Inc (ACET) .

Click here to see the complete history of Blake Aftab’s form 4 insider trades.

Insider Ownership Summary of Blake Aftab

Ticker Comapny Transaction Date Type of Owner
ACET Adicet Bio Inc 2022-11-10 Chief Scientific Officer

Blake Aftab Latest Holdings Summary

Blake Aftab currently owns a total of 1 stock. Blake Aftab owns 28,209 shares of Adicet Bio Inc (ACET) as of November 10, 2022, with a value of $47,391.

Latest Holdings of Blake Aftab

Ticker Comapny Latest Transaction Date Shares Owned Current Price ($) Current Value ($)
ACET Adicet Bio Inc 2022-11-10 28,209 1.68 47,391

Holding Weightings of Blake Aftab


Blake Aftab Form 4 Trading Tracker

According to the SEC Form 4 filings, Blake Aftab has made a total of 6 transactions in Adicet Bio Inc (ACET) over the past 5 years, including 0 buys and 6 sells. The most-recent trade in Adicet Bio Inc is the sale of 6,967 shares on November 10, 2022, which brought Blake Aftab around $146,307.

Insider Trading History of Blake Aftab

No transactions are available. GuruFocus only tracks and displays the purchase and sale of non-derivative security in open market or private transactions from SEC filings with the transaction code of P or S.
Total 0
  • 1
Only the transactions in Open Market or Private Sale at the market prices are included. Other transactions such as conversion of derivative security or exercise of options are not included. Insiders are limited to only officers and/or directors of the company.

Blake Aftab Trading Performance

Please note GuruFocus will not track the insiders’ transaction performance if he/she does not have buying transactions.

Blake Aftab Ownership Network

Ownership Network List of Blake Aftab

No Data

Ownership Network Relation of Blake Aftab


Blake Aftab Owned Company Details

What does Adicet Bio Inc do?

Who are the key executives at Adicet Bio Inc?

Blake Aftab is the Chief Scientific Officer of Adicet Bio Inc. Other key executives at Adicet Bio Inc include director & 10 percent owner Orbimed Advisors Llc , director & See Remarks Chen Schor , and Chief Technology Officer Don Healey .

Adicet Bio Inc (ACET) Insider Trades Summary

Over the past 18 months, Blake Aftab made 1 insider transaction in Adicet Bio Inc (ACET) with a net sale of 6,967. Other recent insider transactions involving Adicet Bio Inc (ACET) include a net sale of 95,268 shares made by Chen Schor , a net purchase of 4,000,000 shares made by Carl L Gordon , and a net purchase of 4,000,000 shares made by Orbimed Advisors Llc .

In summary, during the past 3 months, insiders sold 0 shares of Adicet Bio Inc (ACET) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 128,235 shares of Adicet Bio Inc (ACET) were sold and 8,016,000 shares were bought by its insiders, resulting in a net purchase of 7,887,765 shares.

Adicet Bio Inc (ACET)'s detailed insider trading history can be found in Insider Trading Tracker table.

To

Adicet Bio Inc Insider Transactions

No Available Data

Blake Aftab Mailing Address

Above is the net worth, insider trading, and ownership report for Blake Aftab. You might contact Blake Aftab via mailing address: C/o Adicet Bio, Inc., 200 Clarendon Street, Floor 6, Boston Ma 02116.

Discussions on Blake Aftab

No discussions yet.